We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bilanz Biontech 2022: Impfstoffe und Onkologie.
- Authors
Bulmahn, Maren
- Abstract
The Mainz-based company Biontech achieved a revenue of approximately 17.31 billion euros in 2022, which corresponds to a decrease of 8.8 percent compared to the previous year. Costs increased to 2.99 billion euros. Net profit decreased from 10.29 billion euros to approximately 9.43 billion euros. Biontech continues to invest in the development of vaccines, particularly against malaria, and is expanding its drug pipeline for various types of cancer. The company is also working on an immunomodulator in collaboration with the US biopharmaceutical company OncoC4. Biontech plans to expand its commercial capacities in oncology and conduct approval studies to allow multiple oncology products in cancer indications with high medical need.
- Subjects
MAINZ (Germany : Landkreis); BIONTECH SE; PHARMACEUTICAL biotechnology industry; CLINICAL indications; VACCINE development; CORPORATE profits; EURO; MALARIA
- Publication
Nachrichten aus der Chemie, 2023, Vol 71, Issue 5, p34
- ISSN
1439-9598
- Publication type
Article
- DOI
10.1002/nadc.20234135281